Broken Arrow Physical Therapy | |
3341 S Elm Pl, Broken Arrow, OK 74012-7924 | |
(918) 449-1332 | |
(918) 449-8732 |
Full Name | Broken Arrow Physical Therapy |
---|---|
Type | Facility |
Speciality | Clinic/center - Physical Therapy |
Location | 3341 S Elm Pl, Broken Arrow, Oklahoma |
Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1114933561 | NPI | - | NPPES |
1578778353 | Other | OK | DME NPI |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225100000X | Physical Therapist | (* (Not Available)) | Secondary |
261QP2000X | Clinic/center - Physical Therapy | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Broken Arrow Physical Therapy 1300 W Sam Houston Parkway, Suite 300, Houston, TX 77042 Ph: (713) 297-7000 | Broken Arrow Physical Therapy 3341 S Elm Pl, Broken Arrow, OK 74012-7924 Ph: (918) 449-1332 |
News Archive
Children who experience family and environmental stressors, and traumatic experiences, such as poverty, mental illness and exposure to violence, are more likely to be diagnosed with Attention Deficit/Hyperactivity Disorder (ADHD), according to new research by investigators at the Children's Hospital at Montefiore, titled "Associations Between Adverse Childhood Experiences and ADHD Diagnosis and Severity," published in Academic Pediatrics.
Renowned public health specialist, Professor Stephen Leeder, will present the central findings of a report highlighting the disturbing trend towards a growth in cardiovascular disease in developing countries, at a special colloquium to be held at The University of Sydney.
About one in 8,000 people have facioscapulohumeral muscular dystrophy, according to a 2014 study, which is relatively common in the world of genetic diseases.
NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostic products, today announced positive results from the second clinical validation study of its in vitro diagnostic breast cancer assay based on the PAM50 gene expression signature.
› Verified 1 days ago